Follow
Nour Majbour
Nour Majbour
MRC Prion Unit at UCL
Verified email at ucl.ac.uk - Homepage
Title
Cited by
Cited by
Year
Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
NK Majbour, NN Vaikath, KD Van Dijk, MT Ardah, S Varghese, ...
Molecular neurodegeneration 11, 1-15, 2016
2522016
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
O Hansson, S Hall, A Öhrfelt, H Zetterberg, K Blennow, L Minthon, ...
Alzheimer's research & therapy 6, 1-6, 2014
2162014
Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
L Parnetti, L Farotti, P Eusebi, D Chiasserini, C De Carlo, D Giannandrea, ...
Frontiers in aging neuroscience 6, 53, 2014
1842014
Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
MF Duffy, TJ Collier, JR Patterson, CJ Kemp, KC Luk, MG Tansey, ...
Journal of neuroinflammation 15, 1-18, 2018
1812018
Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
M Karampetsou, MT Ardah, M Semitekolou, A Polissidis, M Samiotaki, ...
Scientific reports 7 (1), 16533, 2017
1522017
Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology
NN Vaikath, NK Majbour, KE Paleologou, MT Ardah, E van Dam, ...
Neurobiology of disease 79, 81-99, 2015
1472015
Parkinson’s disease biomarkers based on α‐synuclein
M Fayyad, S Salim, N Majbour, D Erskine, E Stoops, B Mollenhauer, ...
Journal of neurochemistry 150 (5), 626-636, 2019
1322019
Longitudinal changes in CSF alpha‐synuclein species reflect Parkinson's disease progression
NK Majbour, NN Vaikath, P Eusebi, D Chiasserini, M Ardah, S Varghese, ...
Movement Disorders 31 (10), 1535-1542, 2016
1152016
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
D Volc, W Poewe, A Kutzelnigg, P Lührs, C Thun-Hohenstein, ...
The Lancet Neurology 19 (7), 591-600, 2020
1062020
Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice
M Helwig, M Klinkenberg, R Rusconi, RE Musgrove, NK Majbour, ...
Brain 139 (3), 856-870, 2016
1052016
α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
I van Steenoven, NK Majbour, NN Vaikath, HW Berendse, ...
Movement Disorders 33 (11), 1724-1733, 2018
912018
Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy
O El-Agnaf, C Overk, E Rockenstein, M Mante, J Florio, A Adame, ...
Neurobiology of disease 104, 85-96, 2017
872017
CSF or serum neurofilament light added to α‐synuclein panel discriminates Parkinson's from controls
LP Oosterveld, IMW Verberk, NK Majbour, OM El‐Agnaf, HC Weinstein, ...
Movement Disorders 35 (2), 288-295, 2020
772020
α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
SS Ghanem, NK Majbour, NN Vaikath, MT Ardah, D Erskine, NM Jensen, ...
Proceedings of the National Academy of Sciences 119 (15), e2109617119, 2022
732022
Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
JO Aasly, KK Johansen, G Brønstad, BJ Warø, NK Majbour, S Varghese, ...
Frontiers in Aging Neuroscience 6, 248, 2014
702014
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects
JJ Tomlinson, B Shutinoski, L Dong, F Meng, D Elleithy, NA Lengacher, ...
Journal of neural transmission 124, 721-738, 2017
572017
Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
NK Majbour, D Chiasserini, NN Vaikath, P Eusebi, T Tokuda, ...
Scientific reports 7 (1), 40263, 2017
532017
Development of nonviral vectors targeting the brain as a therapeutic approach for Parkinson's disease and other brain disorders
H Javed, SA Menon, KM Al-Mansoori, A Al-Wandi, NK Majbour, MT Ardah, ...
Molecular Therapy 24 (4), 746-758, 2016
492016
CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
NK Majbour, JO Aasly, E Hustad, MA Thomas, NN Vaikath, N Elkum, ...
Translational neurodegeneration 9, 1-10, 2020
402020
A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
N Landeck, H Hall, MT Ardah, NK Majbour, OMA El-Agnaf, G Halliday, ...
Molecular neurodegeneration 11, 1-23, 2016
392016
The system can't perform the operation now. Try again later.
Articles 1–20